E-Z-EM Congratulates ACRIN on Completion of Virtual Colonoscopy Study

E-Z-EM, Inc., (Nasdaq:EZEM) announced today that the American College of Radiology Imaging Network (ACRIN) has completed its National CT Colonography Trial and announced its top line findings. The trial–the largest to evaluate virtual colonoscopy as a primary screening option for colorectal cancer conducted to date–found virtual colonoscopy to be “highly accurate for detection of intermediate and large polyps,” and that the accuracy is comparable to optical colonoscopy. The formal study results have been submitted for publication, and will be presented in greater detail at major medical conferences in the coming months.

Commenting on the announcement, Anthony A. Lombardo, President and CEO of E-Z-EM, said, “We are very pleased with the successful completion of this landmark study. As we have reported earlier, E-Z-EM products — PROTOCO2LTM carbon dioxide insufflation system and Tagitol VTM tagging contrast — were used as the clinical standards in this study, along with the other products in our offerings for virtual colonoscopy. We see the results announced today as important validation for virtual colonoscopy as a screening modality, and of the role E-Z-EM products can play in achieving optimum results for physicians and their patients.

“E-Z-EM has been involved in the development and clinical validation of virtual colonoscopy for over 13 years. Throughout this time, we have supported the development of this modality through numerous research grants and through our support for the Centers of Excellence continuing education program, a program that has trained over 400 physicians from around the world in best practices for virtual colonoscopy.

“We believe that the results released today are an important step toward obtaining Federal reimbursement for virtual colonoscopy as a screening modality, and that such reimbursement is critical to establishing the modality as a screening tool for colorectal cancer. We look forward to working with ACRIN in ongoing support of the modality and in securing reimbursement for screening.”

About E-Z-EM, Inc.

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company is the developer of VoLumen®, the next generation, low-density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and Positron Emission Tomography (PET/CT) studies. The Company also offers Empower®―the only family of CT injectors on the market with patented EDA™ technology that can help detect contrast extravasation―and offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system. The Company is also the exclusive worldwide manufacturer and marketer of RSDL™ for first-responder organizations and military services. RSDL is a patented, broad-spectrum liquid chemical warfare (CW) agent decontaminant, that neutralizes or removes chemical agents from skin on contact, leaving a non-toxic residue that can be rinsed off with water.

The statements made in this document contain certain forward-looking statements. Words such as “expects,”"intends,”"anticipates,”"plans,”"believes,”"seeks,”"estimates” or variations of such words and similar expressions, are intended to identify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company’s control. Such risks and uncertainties include: the ability of the Company to develop its products; market acceptance and future sales for virtual colonoscopy related products resulting from positive results of the ACRIN II trial for virtual colonoscopy, the prospect and future timing of CMS reimbursement for virtual colonoscopy screening, possible market acceptance and sales of VoLumen®; future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, price increases of raw materials and components, foreign currency exchange rate fluctuations as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Annual Report on Form 10-K for the fiscal year ended June 2, 2007. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.

NOTE TO EDITORS: In the product name PROTOCO2LTM noted in this news release, the numeral 2 should appear as a subscript. This symbol may not appear properly in some systems.